利妥昔单抗治疗对类固醇无反应的严重甲状腺眼病失败1例 - Suppr

Suppr

超能文献

Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids.

作者信息

Krassas Gerasimos E, Stafilidou Aliki, Boboridis Kostas G

出版信息

Clin Endocrinol (Oxf). 2010 Jun;72(6):853-5. doi: 10.1111/j.1365-2265.2009.03762.x. Epub 2009 Dec 18.

DOI:10.1111/j.1365-2265.2009.03762.x

PMID:20039891

Abstract

摘要

相似文献

Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids.

Clin Endocrinol (Oxf). 2010 Jun;72(6):853-5. doi: 10.1111/j.1365-2265.2009.03762.x. Epub 2009 Dec 18.

Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.

Eur J Endocrinol. 2006 Apr;154(4):511-7. doi: 10.1530/eje.1.02119.

[Biological treatment options for Graves' ophthalmopathy].

Ugeskr Laeger. 2008 Jun 9;170(24):2128-30.

Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.

Eur J Endocrinol. 2007 Jan;156(1):33-40. doi: 10.1530/eje.1.02325.

Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy.

Acta Ophthalmol. 2009 Nov;87(8):927-9. doi: 10.1111/j.1755-3768.2009.01647.x.

Rituximab for thyroid eye disease.

Ophthalmology. 2011 Apr;118(4):792; author reply 792-3. doi: 10.1016/j.ophtha.2011.01.012.

Immunotherapy for Graves' ophthalmopathy.

Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):409-14. doi: 10.1097/MED.0000000000000097.

Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab.

Endocr Metab Immune Disord Drug Targets. 2018;18(6):665-667. doi: 10.2174/1871530318666180702150243.

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.

J Clin Endocrinol Metab. 2007 May;92(5):1769-72. doi: 10.1210/jc.2006-2388. Epub 2007 Feb 6.

Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease.

Leuk Lymphoma. 2007 Mar;48(3):623-4. doi: 10.1080/10428190601094362.

引用本文的文献

Dysthyroid optic neuropathy: emerging treatment strategies.

J Endocrinol Invest. 2023 Jul;46(7):1305-1316. doi: 10.1007/s40618-023-02036-0. Epub 2023 Feb 18.

Rituximab for thyroid-associated ophthalmopathy.

Cochrane Database Syst Rev. 2022 Jun 16;6(6):CD009226. doi: 10.1002/14651858.CD009226.pub3.

Updates on the understanding and management of thyroid eye disease.

Ther Adv Ophthalmol. 2021 Jun 30;13:25158414211027760. doi: 10.1177/25158414211027760. eCollection 2021 Jan-Dec.

Rituximab in the Treatment of Thyroid Eye Disease: A Review.

Neuroophthalmology. 2015 Jun 17;39(3):109-115. doi: 10.3109/01658107.2015.1039140. eCollection 2015 Jun.

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Eur Thyroid J. 2016 Mar;5(1):9-26. doi: 10.1159/000443828. Epub 2016 Mar 2.

Randomized controlled trial of rituximab in patients with Graves' orbitopathy.

J Clin Endocrinol Metab. 2015 Feb;100(2):432-41. doi: 10.1210/jc.2014-2572. Epub 2014 Oct 24.

Graves' orbitopathy: Management of difficult cases.

Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S150-2. doi: 10.4103/2230-8210.104026.

Pathogenesis of Graves' orbitopathy: a 2010 update.

J Endocrinol Invest. 2010 Jun;33(6):414-21. doi: 10.1007/BF03346614.

Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Clin Endocrinol (Oxf). 2011 Jan;74(1):1-8. doi: 10.1111/j.1365-2265.2010.03806.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids.

Clin Endocrinol (Oxf). 2010 Jun;72(6):853-5. doi: 10.1111/j.1365-2265.2009.03762.x. Epub 2009 Dec 18.

Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.

Eur J Endocrinol. 2006 Apr;154(4):511-7. doi: 10.1530/eje.1.02119.

[Biological treatment options for Graves' ophthalmopathy].

Ugeskr Laeger. 2008 Jun 9;170(24):2128-30.

Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.

Eur J Endocrinol. 2007 Jan;156(1):33-40. doi: 10.1530/eje.1.02325.

Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy.

Acta Ophthalmol. 2009 Nov;87(8):927-9. doi: 10.1111/j.1755-3768.2009.01647.x.

Rituximab for thyroid eye disease.

Ophthalmology. 2011 Apr;118(4):792; author reply 792-3. doi: 10.1016/j.ophtha.2011.01.012.

Immunotherapy for Graves' ophthalmopathy.

Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):409-14. doi: 10.1097/MED.0000000000000097.

Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab.

Endocr Metab Immune Disord Drug Targets. 2018;18(6):665-667. doi: 10.2174/1871530318666180702150243.

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.

J Clin Endocrinol Metab. 2007 May;92(5):1769-72. doi: 10.1210/jc.2006-2388. Epub 2007 Feb 6.

Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease.

Leuk Lymphoma. 2007 Mar;48(3):623-4. doi: 10.1080/10428190601094362.

引用本文的文献

Dysthyroid optic neuropathy: emerging treatment strategies.

J Endocrinol Invest. 2023 Jul;46(7):1305-1316. doi: 10.1007/s40618-023-02036-0. Epub 2023 Feb 18.

Rituximab for thyroid-associated ophthalmopathy.

Cochrane Database Syst Rev. 2022 Jun 16;6(6):CD009226. doi: 10.1002/14651858.CD009226.pub3.

Updates on the understanding and management of thyroid eye disease.

Ther Adv Ophthalmol. 2021 Jun 30;13:25158414211027760. doi: 10.1177/25158414211027760. eCollection 2021 Jan-Dec.

Rituximab in the Treatment of Thyroid Eye Disease: A Review.

Neuroophthalmology. 2015 Jun 17;39(3):109-115. doi: 10.3109/01658107.2015.1039140. eCollection 2015 Jun.

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Eur Thyroid J. 2016 Mar;5(1):9-26. doi: 10.1159/000443828. Epub 2016 Mar 2.

Randomized controlled trial of rituximab in patients with Graves' orbitopathy.

J Clin Endocrinol Metab. 2015 Feb;100(2):432-41. doi: 10.1210/jc.2014-2572. Epub 2014 Oct 24.

Graves' orbitopathy: Management of difficult cases.

Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S150-2. doi: 10.4103/2230-8210.104026.

Pathogenesis of Graves' orbitopathy: a 2010 update.

J Endocrinol Invest. 2010 Jun;33(6):414-21. doi: 10.1007/BF03346614.

Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab.

Clin Endocrinol (Oxf). 2011 Jan;74(1):1-8. doi: 10.1111/j.1365-2265.2010.03806.x.